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Abstract
Ethical questions with regard to treatment arise when pregnant women are diagnosed with cancer. Does the health of
the mother or the health of the fetus take priority? However, research suggests that concern over transplacental transfer
should not deter those seeking treatments since avoidance of favorable transfer drugs can allow chemotherapy to be
a viable option if properly administered. Doctors highly contraindicate the use of chemotherapeutic drugs in the first
trimester due to high risks such as teratogenesis and fetal death. However, they reassure that treatment can be given in
the final two trimesters. It presents minimal consequences as long as the drug is not favorably transferred, treatment is
not given after thirty five weeks, and delivery is not less than three weeks after chemotherapy administration. Iatrogenic
prematurity should also be avoided. Additionally, long term risks are minimal, but further research needs to be performed
with longer follow ups and larger sample sizes in studies in order to obtain more conclusive data.
Introduction
There has been an increase in treating pregnant women with
cancer and scientists suggest that the change in trend is due to
older women conceiving. Reports indicate that cancer is diagnosed in approximately 1 in 1000-1500 pregnancies (Voulgaris,
et al., 2011). If cancer treatment cannot be postponed until after
birth, ethical concerns arise with regard to the health of the
mother and fetus, and so the benefits and side-effects need to be
discussed by patient, oncologist, and obstetrician. Factors that impact treatment include cancer type and stage, gestational age and
consequences of treatment on the mother and fetus. In addition,
risks, treatments and, if necessary, the option of abortion must be
determined. The goal is to determine if and at what gestational
age treatment should be given, whether cytotoxic drugs administered to the mother impacts the development of the fetus and
results in long-term risks for the child.

Methods
Information and research was obtained through Ebsco, Proquest
and Pubmed. Access was provided by Touro College library. Main
key words included pregnancy, short-term, long-term, transplacental, in utero, fetus, and chemotherapy.

Discussion
Transplacental Transfer
To first address the impact of transplacental transfer, it is essential to determine if there is drug transfer between the mother
and the fetus, and if so, to what extent. A mouse model using 40
pregnant mice was studied to determine the amount of transplacental transfer of chemotherapeutic agents, doxorubicin, epirubicin, cytarabine, paclitaxel, carboplatin and vinblastine. Due to
the difference of drug metabolism in mice, the drugs were given
at proportionately higher dosages than when given to humans.
Fetal and maternal blood was collected on day eighteen and a
half, during the phase of fetal development. The mice were delivered by caesarean section ninety minutes (an arbitrary amount
of time) after chemotherapeutic drugs were intravenously given
to the mother. At this point in time, an increase in plasma levels

ensured drug detection and was the first phase of distribution
after the drugs were intravenously administered. The drug levels in the maternal and fetal plasma were detected using two
methods. High performance liquid chromatography determined
the amount of the five chemotherapy drugs and Atomic absorption spectrometry determined carboplatin levels, based on the
amount of platinum in the blood.

Plasma Drug Analysis
Paclitaxel was found in maternal plasma, but was not detected
in fetal plasma. It has a high molecular weight, is highly protein
bound and is a substrate of P—glycoprotein (ATP-binding cassette transporters) and multidrug resistance protein. P—glycoprotein is found in fetal-derived epithelial cells which forms the
maternal-fetal blood exchange border and protects the fetus.
Vinblastine and anthracyclines, which includes epirubicin, a
4′-epimer of doxorubicin, and doxorubicin, only presents as a
small transfer ratio due to being P-glycoprotein substrate, which
protects the fetus against xenobiotics’ harmful effects. Another
factor is that it possesses pharmokinetic properties that contrast
to the substances that cross the placenta. Thus, one can imply
that vinblastine, anthacyclines and paclitaxel present a safe option
for treatment when given in small dosages during the last two
trimesters.
However, both carboplatin and cytarabine have high transfer rates
and can penetrate the membranes barriers since they are slightly
bound and have a low molecular weight. Therefore, researchers
recommended, if possible, avoiding these drugs (Calsteren, et al.,
2010;Van Calsteren et al., 2010)
The transplacental transfer is generally through passive diffusion
and is typically penetrable. However, there are three factors that
influence the maternal-fetal transfer. They are: (1) maternal and
fetal circulation concentration gradient, (2) the placental blood
flow, and (3) chemotherapy’s drug properties. The pharmokinetics of chemotherapy that favor transplacental transfer are
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uncharged, low molecular weight, lipid soluble, and unbound or
low protein bound compounds (Calsteren, et al., 2011).

Maternal- Fetal Transfer in a Baboon Model
The data obtained from the previous experiment, however, is
limited in its clinical application due to the differences of human
and mouse metabolism and permeability and formation of the
placenta (Van Calsteren, et al., 2011). This elicited further investigation of the effects of maternal-fetal transfer of chemotherapeutic agents given in second and third trimesters. Two studies,
using the same subjects, examined the results of different chemotherapeutic drugs on a group of nine pregnant baboons. Data
more relevant to humans can be obtained from baboon models
as compared to mice models due to the greater similarity of
human and baboon embryological development, placental structure and function, reproductive physiology and endocrinology of
pregnancy and drug metabolism. Based on the outcome, since
only low levels were detected, the authors were reassured that
the use of doxorubicin, epirubicin, vinblastine, taxanes (docetaxel
and paclitaxel) and active metabolite of cyclophosphamide (4OHPC) were not damaging to the fetus. However, they were
concerned with the results of trastuzumab and carboplatin since
they were transferred in large or complete amounts. The study
was limited since there was no record of long term results, and
it was suggested that further research needed to be performed
(Calsteren, et al., 2010). Furthermore, other medical professionals contraindicate trastuzumab since it has been correlated with
oligohydramnios, reduced production of amniotic fluid resulting
from the drug binding to fetal renal receptors (Gziri, et al., 2012).

Placental Perfusion Model
As it would be unethical to perform human testing on pregnant
women to determine whether there is maternal-fetal transfer
due to fetal risk of fetal blood sampling from the umbilical cord
known as cordocentesis, Van Calsteren et al. (2011) suggested
that they can be applied to a single cotyledon models that have
separate fetal and maternal circulations. Unfortunately, some
complications with this proposal included difficulties obtaining
absolute physiological conditions in a perfusion system, temporary status of tissue viability, and the differences in data between
in vivo and placenta perfusion model with some drugs (Myllynen,
Vhakangas, 2002;Van Calsteren, et al., 2011).
An attempt was made, however, to examine the effects of maternal-fetal transfer of taxanes (paclitaxel and docetaxel) to determine whether it can be a viable treatment option. The single
cotyledons were taken from twelve placentas from uneventful
pregnancies with each test group containing six models. The test
groups were further divided into two groups of three, with one
group containing high concentration of albumin (30 g/L) and the
other group with low concentration of albumin (2 g/L). In the
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intervillous space two catheters were inserted to begin the perfusion and the twelve placentas were perfused for ninety minutes. The results indicated that taxanes have a low transplacental
transfer due to their chemical properties and added that there
was no difference in amount of drug transfer between paclitaxel
and docetaxel. Furthermore, the outcome between the groups of
high and low levels of albumin reinforced the theory that protein
levels affect the maternal-fetal transfer. This was supported with
the observation of less transfer of both docetaxel and paclitaxel
with high levels of albumin. Although this reinforced previous
studies of placental transfer, sample size was too small and further investigation should be performed (Berveiller, et al., 2012).

Factors and Effects of Chemotherapeutic Drugs
Based on research that positively indicated transplacental transfers of chemotherapeutic drugs, studies were initiated to determine the drug effect on the developing fetus.There are four main
drugs that are typically administered to pregnant cancer patients.
They are: anthracyclines (e.g., doxorubicin, epirubicin), platinum-based antineoplastics (e.g., cisplatin, carboplatin), cyclophosphamide and taxanes (e.g., paclitaxel, docetaxel). Anthracyclines
result in cardiotoxicity and inhibit topoisomerase, interfering
with DNA replication. Platinum based antineoplastics result in
neurotoxicity and ototoxicity if given at high doses. It also allows
for apoptosis to occur since it binds to and causes crosslinking of
DNA. The effect of cyclophosphamide is permanent infertility if
given at high dosage. Lastly, taxanes disrupt the microtubule function in cell division thereby inhibiting mitosis (Vandenbroucke, et
al., 2014). The overall similarity between them is that they halt
normal cell proliferation cycles which results in interrupting crucial cell processes. Studies on somatic cell mutations report that
some adverse effects of chemotherapy are gene mutations, chromosomal breaks and rearrangements, and aneuploidy (Arnon, et
al., 2001).
The impact of chemotherapy on the fetus can vary due to physiologic changes in the pregnant patient. Some examples that may
occur include an increase in glomerular filtration, which increases
the amount of elimination or drug excreted by the kidney, and an
increase of drug metabolization in the liver, which might impact
the presence of active drugs. Additionally, there is an increase in
entero-hepatic circulation in pregnant women. This causes active
metabolites to return to the liver and then colon after being
secreted from bile into the colon and reabsorbed by enterocytes.
The circulation prolongs the drug exposure since it lengthens
the time needed to eliminate the drug from the body because it
returns to the blood stream.The amount of active drugs available
can decrease due to an increase in protein binding which results
in a greater impact of cytotoxic drugs. However, plasma levels
of cytotoxic drugs may be reduced as a result of an increase in
plasma concentration (Amant, et al., 2008). The third space that
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develops in pregnant women resulting from an increase of amniotic fluid can also impact the distribution volume of chemotherapy, causing a slow release of drug which results in an increase
of fetal chemotherapy exposure (Williams, Schilsky, 2000). Other
factors that impact the maternal chemotherapy on the fetus are
metabolic activity and excretion of the placenta, increase of body
fat of the pregnant patient and pH difference between maternal
and fetal fluids (Gedeon, Koren, 2006). When creating a treatment plan, these physiologic changes must be considered.
Various other factors can also result in teratogenic risks to the
fetus. Although the placenta can excrete fetal waste products and
assist in fetal drug elimination, some antineoplastic agents may
not be eliminated from the fetus if drugs are administered close
to delivery time. Additionally, due to the fetus’s immature liver
and kidney, the fetal metabolism and excretion of the chemotherapeutic drugs may be abnormal.This can result in an increase
of chemotherapy exposure and acute toxicity (Williams, Schilsky,
2000).

there is a 10-20% chance of teratogenicity, fetal malformation,
occurring if agents are administered in the first trimester. An increase of embryonic death can occur if there is damage to the
embryo in the first month of gestation resulting from chemotherapy exposure (Voulgaris, et al., 2011). Spontaneous abortion and
major malformations are also possible risks that can occur. The
fetus is more susceptible to malformations two to eight weeks
after conception, the period of organogenesis. Specifically, the
heart, neural tube, and limbs are more vulnerable, preceding the
palate and ears of the fetus. If chemotherapy exposure continues
after eight weeks, the eyes, genitalia, hematopoietic and central
nervous system still remain at risk (Cardonick, Iacobucci, 2004).
This strongly reinforces that maternal chemotherapy should be
avoided in the first trimester.

Chemotherapy Exposure- Fetal Phase of
Development

The effect on the fetus is not only dependent on drug type and
performance, but is also based on dose, route and gestational
age. Studies have proven higher toxicity can develop from short
infusions, topically applied cytotoxic agents and intraperitoneal
administration.¬ Drugs given orally may be absorbed less due
to a decrease of elimination from the stomach and intravenous
administration can result in fetal risks. As mentioned previously,
prolonged drug elimination from the mother also impacts the
toxicity on the fetus (Wiebe, et al., 1994).

Based on observations of the fetus exposed to maternal chemotherapy during the final two trimesters, researchers have
suggested that these exposed fetuses did not exhibit more
congenital malformations than fetuses from untreated mothers.
Nevertheless, intrauterine growth restriction, low birth weight
and neonatal myelosuppression have been detected in neonates
exposed to chemotherapy in the second and third trimester
(Cardonick, Iacobucci, 2004; Van Calsteren, et al., 2011). From
week eleven until delivery, functional damage will frequently
occur as a result of cell death. In addition, some organs may later
develop structural anomalies. For instance, the fetus can develop
neuropsychological impairment since the central nervous system
is progressing throughout gestation (Vandenbroucke, et al., 2014).

Chemotherapy Exposure- Fertilization/
Implantation

Short-term Effects -Obstetric and Neonatal
Outcomes

To determine the effect of chemotherapy on the developing
embryo and fetus, observations were performed during the
three stages of pregnancy. The three phases of fetal development are fertilization/implantation, organogenesis, and the fetal
phase. Chemotherapy is cytotoxic, thereby inhibiting cell growth.
Therefore, exposure during the first ten days of pregnancy, the
stage of fertilization/implantation, results in an all-or-nothing phenomenon. Cells are omnipotent and may develop into the three
different embryological layers, ectoderm, mesoderm and endoderm. However, their ability to develop normally is dependent
on the impact of maternal chemotherapy. If there is a sufficient
amount of cells, the embryo will develop normally, but a miscarriage can occur if too many cells are destroyed by the chemotherapeutic drug (Reed, et al., 2010).

One study reported on 62 patients who were treated predominantly in the last two trimesters with chemotherapy alone or
combined with other treatments, such as radiotherapy. These
patients were part of a sample of 180 pregnant women who received various treatments for cancer. The results were analyzed
to determine the fetal risks of treated and untreated mothers
diagnosed with cancer.

Administration Variables

Chemotherapy Exposure- Organogenesis
During the first trimester, it is highly inadvisable to treat the
mother with cytotoxic drugs. Voulgaris et al. reports (2011) that

Regarding patients treated with chemotherapy, there was a significant increase in preterm labor, but not in the rate of preterm
premature rupture of membranes (PPROM) when compared to
neonates not exposed to maternal chemotherapy. However, the
only incidents of preterm labor and PPROM that occurred in the
180 cases analyzed involved patients treated with chemotherapy.
Preterm labor can occur from the activation of hypothalamic-pituitary-adrenal axis of either the mother or fetus resulting from
physical or psychological stress. Scientists propose that PPROM
can result from apoptosis in amnion epithelial and chorion
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trophoblast layers of the membranes after maternal chemotherapy exposure (Van Calsteren, et al., 2010).
The risks of preterm labor include intraventricular hemorrhage,
bradycardia, apnea, respiratory insufficiency, necrotizing enterocolitis, sepsis, seizures, hypoglycemia, and feeding problems (Van
Calsteren, et al., 2010). Additionally, Johnson (2007) reported
that preterm births are associated with a decrease in IQ scores,
cognitive delay, behavioral problems and higher risk for psychiatric disorders, primarily ADHD. Preterm labor in this research was
preventable since several of the neonatal issues were iatrogenic.
Therefore, researchers suggested that patients that can delay
treatment until after delivery should do so to avoid prematurity
(Van Calsteren, et al., 2010).
Data of small-for-gestational-age children was available for only
175 neonates. Regarding those treated with cytotoxic treatments
(chemotherapy and/or radiotherapy), 16 of 66 children were
small- for- gestational age as opposed to 10 of 109 children who
were not exposed to maternal chemotherapy/radiotherapy.
The malformation outcome in comparison to normal pregnancies reveals that there was no significant increase in rate. The
range of physical abnormalities of neonates exposed to maternal
chemotherapy was still within normal range, with 2 of 66 (3.0%)
inflicted with major malformations and 5 of 66 (7.5%) affected
with minor malformations. The average rate of major and minor
malformations was 4.1% to 6.9% and 6.5% to 35.8%, respectively.
This suggests that the concern of malformation defects due to
chemotherapy is not applicable and should not deter patients
from avoiding treatment (Van Calsteren, et al., 2010).
Another fetal risk that may occur is transient neonatal myelosupression (TNM). Elburg et al. (2008) defined TNM as “leukopenia
and/or neutropenia combined with anemia and/or thrombocytopenia, during the first weeks of life in newborns exposed to
maternal chemotherapy during pregnancy.” The disease is rare,
potentially life-threatening and may not necessarily develop
right after birth. Additionally, it may pose a risk for developing
infections. The development of TNM may result from a short gap
between chemotherapy administration and birth, maternal neutropenia at delivery, type of chemotherapy and maternal disease
and dosage given. Treatments for TNM include thrombocyte and/
or erythrocyte transfusions, bedside isolation, erythropoietin,
and recombinant human granulocyte colony stimulating factors
(G-CSF). In a study of fifteen neonates diagnosed with TNM,
only one died due to infection resulting from TNM. However,
the other fourteen neonates’ physical and neurological developments were normal by the age of one and their TNM was
resolved between two to ten weeks after birth. Generally, there
is no difference detected in short term outcomes and survival

22

rates between neonates exposed to chemotherapy that develop
TNM and those not diagnosed with TNM. Researchers stated
that this is true as long as the disease is recognized and aggressive
treatment is given. However, the long-term consequences are still
unknown (Udink ten Cate, et al., 2009).
Another study performed by Aviles et al. (1991) consisted of
43 infants exposed to maternal chemotherapy. The infants were
examined from age three through nineteen years old and it was
observed that only eight were pancytopenic at birth, which characterizes them as being deficient in red and white blood cells
and platelets. However, the mothers of these neonates were
treated with chemotherapy in the last three weeks prior to delivery which disputes the suggestion that a short gap between
chemotherapy administration and delivery results in TNM. There
were no congenital anomalies and neurological abnormalities reported and like the findings of the Udink ten Cate et al. (2009)
study, the TNM resolved 2-10 weeks after birth. In addition, in a
study of 62 patients, two children suffered postnatal hematologic toxicity (leukopenia and pancytopenia) when born ten days
after maternal chemotherapy administration for acute lymphatic
leukemia and required hematologic growth factors as treatment
(Calsteren, et al., 2010). This study supports the theory, unlike
Aviles et al. (1991) that a short interval between the chemotherapy administration and delivery can result in hematologic toxicity.
As seen with these results, hematologic toxicity can present a
slight concern for pregnant women with cancer, yet the risks are
minimal if proper treatment is given.
Cardonick and Iacobucci (2004) have studied the impact of chemotherapy given after the first trimester on 376 fetuses. Of the
376, nineteen of the fetuses and four of the neonates died, 28
neonates were born with intrauterine growth restriction and 18
were born prematurely (iatrogenic cases excluded). Additionally,
two were diagnosed with transient neonatal cardiomyopathy due
to maternal idarubicin treatment, fifteen neonates developed
transient neonatal myelosuppression. Eleven malformations were
also reported with the majority resulting from chemotherapy
exposure in the first trimester.
Another study was performed which was composed of 61 patients receiving chemotherapy during the second and third trimesters. Of the 61 patients, 32 were treated with neoadjuvant
chemotherapy and 2 received adjuvant chemotherapy. The 61
neonates that were exposed to maternal chemotherapy were
examined and compared to 60 neonates who were born prematurely and were not exposed to maternal chemotherapy. Results
suggested that there were no differences in birth weight, admissions to the NICU, and neonatal survival. No malformations were
reported in either group. Nonetheless, one contrast between the
groups was the considerable difference in Apgar score, which
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tests the future neurobehavioral development first at one minute
after birth, then five minutes after and after ten minutes after
birth. The results favored the group of children not exposed to
chemotherapy at one and five minutes, but there were no significant difference at ten minutes. Although it reflects positive
short-term outcomes, it’s limited in long-term follow up on these
children and researchers suggest further studies need to be performed (Abdel-Hady, et al., 2012).
Fetal cardiotoxicity was also researched to determine whether
it can develop from maternal chemotherapy and pose a threat
to neonates. One study consisted of ten pregnant patients treated with anthracyclines in the last two trimesters to investigate
whether these drugs, which are thought to cause fetal cardiotoxicity, can result in fetal cardiac abnormality. The results indicated
that one fetus was diagnosed with fetal supraventricular tachycardia, but researchers believed it was unrelated to maternal chemotherapy. Additionally, differences in myocardial performance
index and in the tricuspid inflow pattern were detected, but were
considered clinically insignificant. The neurological development
and weight, height, and clinical examination of the fetuses in the
study group were within normal limits. Significant cardiac abnormality and intrauterine growth restriction were not detected, although low birth weight was observed. Although the researchers
gathered data systematically, the study was small and therefore
limited (Gziri, et al., 2012).

Long Term Effects
A concern of maternal chemotherapy is the long-term cardiotoxic
effects on the fetus.A study used tissue Doppler and strain imaging
to identify any specific changes in cardiac performances that might
result from chemotherapeutic drug.The study focused on children
exposed to anthracylines, a drug shown to cause cardiomyopathy
and cardiac dysfunction. The children’s ages ranged from 1-9 years
old, with the mean age being 1.7 years old.Those exposed to anthracyclines were observed to have minor changes in left ventricular
(LV) wall thickness that might have occurred from the effect of
anthracycline’s toxicity. Anthracycline is known to lead to loss of
cardiac muscle. There was also indication that there might be a
lower, but normal ejection fraction and left ventricular ejectional
fractional shortening, which is not clinically important since there
is no change in functionality. Since there were no differences in tissue Doppler and strain imaging between the control group and patients, researchers indicated that there was no change in myocardial function. They stated that changes recorded could have resulted
from the fact that the majority of the neonates born were preterm.
Overall, their observation showed that there was no significant
change between the 62 patients and 62 age gender-matched controls. Researchers recommended further research to observe any
future irregularities and suggested performing further studies with
larger patient groups with proper follow up (Gziri, et. al., 2013).

Further research was performed to assess the neurodevelopment, cardiac function, and general health of 70 children who
were exposed to chemotherapy in utero. Seventy children from
68 pregnancies (two twin pregnancies) were assessed at age 18
months and at ages 5–6, 8–9, 11–12, 14–15, or 18 years. The median gestational age at birth was 35.7 weeks, with a median follow-up period of 22.3 months. Most of the children had normal
cognitive development. However, children who were born prematurely had lower cognitive development scores albeit within
normal range of cognition. Moreover, for each additional month
of gestation, the IQ score increased by an average 11.6 points.
Therefore, iatrogenic preterm delivery is not suggested since it
significantly impacts the cognitive development.
Additionally, because the CNS continues to develop after the
first trimester, the possibility that maternal chemotherapy may
adversely affect neurological development is a serious concern
(Gziri, et al., 2012). However, only one set of twins of 70 children
observed experienced severe neurodevelopmental delay. This
cannot be completely attributed to the exposure to a chemotherapeutic drug (Amant, et al., 2012). The cortex of the fetal
brain develops surface sulci and gyri at 14 weeks gestational age
and doesn’t remain the original smooth cerebral surface.The formation of polymicrogyria, in which the cerebral cortex develops
abnormally before birth in the deeper layers and excessive gyri
form, removes some of the probability that chemotherapy exposure after 15 weeks instigated the developmental delay observed
in the twins (Amant, et al., 2012; Barkovich, et al., 2010). Yet, the
researchers did acknowledge that although the neurodevelopment was normal in the overall researched group, subtle changes
could occur and further research on longer follow-ups should
be conducted.
Nonetheless, the average results of the children’s behavior, general health, hearing, and growth were within the normal range,
along with their cardiac dimensions and functioning. No increase
in CNS morbidity was recorded. Although there were no congenital cardiac abnormalities detected, further study was recommended on the cardiac function since there were clinically small,
but statistically significant changes in ejection fraction, fractional
shortening and diastolic variables. They did detect, however, a
higher incidence of disharmonic intelligence profiles. The results
of the Wechsler test depicted a discrepancy between verbal
and performance IQ values. This was seen in 39% of patients in
comparison to 15% in the normal population. The discrepancy
has been associated with several neurological disorders, learning
problems and behavioral issues.
The study was limited due to the small sample size, short follow-up periods, and lack of children born at the same gestational
age and similarly assessed, who were not prenatally exposed to
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chemotherapy. Additionally, researchers could not predict if secondary malignancy and infertility would have developed due to
time constraint of the experiment. Only one twin, who also had
congenital malformation, was diagnosed with secondary malignancy and suffered from papillary thyroid cancer at age eleven
and neuroblastoma at age fourteen.
Nonetheless, the researchers suggested that chemotherapy not
be administered after 35 weeks since this can trigger spontaneous labor. Delivery, they stated, should be arranged to be no
less than three weeks after the last chemotherapy cycle. This ensures that the bone marrow recuperates properly, prevents the
development of fetal and maternal sepsis and hemorrhage and
hematological toxicity. As mentioned, preterm delivery should be
avoided due to the impact on cognitive development. Preterm
neonates are limited in their capacity to metabolize and eliminate drugs since they have immature liver and kidneys.Therefore,
if delivery can be postponed, the fetus can excrete the drug
through the placenta instead.

it provides concrete evidence that the fetus can escape harm and
develop normally into a healthy accomplishing adult.

Conclusion
Overall, transplacental transfer of cytotoxic drug is not detected in all of the treatments and its impact varies based on the
physiologic changes in pregnant women and the pharmokinetics
of drugs administered. Many emphasize that chemotherapeutic
agents should certainly be delayed and only be given after the
first trimester since the fetus is highly vulnerable to teratogenicity. When given in the final two trimesters, risks can still persist.
However, this should not prevent the mother from seeking treatments due to insignificant short-term and long-term effects.
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